Compare Elder Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA NOVARTIS ELDER PHARMA/
NOVARTIS
 
P/E (TTM) x -0.2 1,946.9 - View Chart
P/BV x 0.1 25.8 0.4% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 ELDER PHARMA   NOVARTIS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
NOVARTIS
Mar-19
ELDER PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs380980 38.8%   
Low Rs188600 31.3%   
Sales per share (Unadj.) Rs491.2198.7 247.2%  
Earnings per share (Unadj.) Rs-3.221.0 -15.2%  
Cash flow per share (Unadj.) Rs14.422.3 64.7%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs376.5307.5 122.4%  
Shares outstanding (eoy) m20.5424.69 83.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.0 14.5%   
Avg P/E ratio x-89.337.7 -236.9%  
P/CF ratio (eoy) x19.735.5 55.5%  
Price / Book Value ratio x0.82.6 29.4%  
Dividend payout %047.7 0.0%   
Avg Mkt Cap Rs m5,83319,508 29.9%   
No. of employees `000NA0.6 0.0%   
Total wages/salary Rs m2,1791,171 186.1%   
Avg. sales/employee Rs ThNM8,445.4-  
Avg. wages/employee Rs ThNM2,015.7-  
Avg. net profit/employee Rs ThNM891.0-  
INCOME DATA
Net Sales Rs m10,0894,907 205.6%  
Other income Rs m257783 32.8%   
Total revenues Rs m10,3465,689 181.8%   
Gross profit Rs m-792123 -644.9%  
Depreciation Rs m36132 1,136.2%   
Interest Rs m2,75616 17,335.2%   
Profit before tax Rs m-3,653858 -425.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125340 36.8%   
Profit after tax Rs m-65518 -12.6%  
Gross profit margin %-7.82.5 -313.6%  
Effective tax rate %-3.439.6 -8.6%   
Net profit margin %-0.610.6 -6.1%  
BALANCE SHEET DATA
Current assets Rs m9,2408,055 114.7%   
Current liabilities Rs m9,9981,850 540.4%   
Net working cap to sales %-7.5126.4 -5.9%  
Current ratio x0.94.4 21.2%  
Inventory Days Days4645 102.9%  
Debtors Days Days6034 176.7%  
Net fixed assets Rs m10,124150 6,758.1%   
Share capital Rs m206123 166.7%   
"Free" reserves Rs m5,5827,469 74.7%   
Net worth Rs m7,7347,592 101.9%   
Long term debt Rs m4,8890-   
Total assets Rs m22,8829,824 232.9%  
Interest coverage x-0.354.9 -0.6%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.5 88.3%   
Return on assets %11.85.4 216.5%  
Return on equity %-0.86.8 -12.4%  
Return on capital %22.311.5 193.9%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30758 532.3%   
Fx outflow Rs m1251,326 9.4%   
Net fx Rs m181-1,269 -14.3%   
CASH FLOW
From Operations Rs m11,754-1,943 -605.0%  
From Investments Rs m-5612,742 -20.4%  
From Financial Activity Rs m-6,762-298 2,267.5%  
Net Cashflow Rs m4,432501 884.0%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 16.8 1.6 1,050.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 21.5 167.9%  
Shareholders   16,479 41,647 39.6%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   WOCKHARDT  J.B.CHEMICALS  ORCHID PHARMA  BIOCON   FULFORD INDIA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; Infosys Dips 4% Post Q4 Results(09:30 am)

Asian share markets are trading on a negative note today following mixed cues from Wall Street.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS